$10.55▴ 2.63%
End-of-day close · 2026-08-06
What most investors miss
Trends, drivers and alerts — the full picture.
Profit → Cash
$-129.45MTTM operating cash
Pre-profit
It is still burning cash while pre-profit.
Valuation
Not enough data yet
Not enough valuation history to place this in context.
Revenue growth
+21664.3%year over year
Strong
Revenue is growing strongly year over year.
Leverage
Not enough data yet
Term-debt data is not available for this company.
More coming: dilution / share-count creep.
✦ The read
4D Molecular Therapeutics, Inc. is pre-profit. It is still burning cash while pre-profit. Revenue is growing strongly year over year.
Key numbers
Valuation
EPS (TTM)$-2.57
TTM (trailing 12 months, through fiscal Q1 FY2026)
Profitability
Net margin-182.3%
TTM (trailing 12 months, through fiscal Q1 FY2026)
Size
Revenue (TTM)$88.24M
TTM (trailing 12 months, through fiscal Q1 FY2026)
Recent news
Sentiment · last 30 days1 article
1 bullish0 neutral0 bearish
4DMT Announces Positive 2-Year Data from PRISM Phase 2b Clinical Trial in a Broad Wet AMD Population
Age-related Macular Degeneration Clinical Trial Pipeline: DelveInsight Highlights Major Advances, Transformative Therapies, and 90+ Leading Players Wheeling the Therapeutics Landscape
Signals and key numbers are from the fiscal Q1 FY2026 filing. Price freshness: end-of-day close on Free, 15-min delayed on Pro.